[ TRANSACTION RECORD ]

Eli Lilly and Company Investment in Oncology Precision Med — 2026

VERIFIED VECTOR ID: 002700 · tx-415
M SOURCE NODE — FUNDER
Eli Lilly and Company
Healthcare United States
$2,500,000,000
EQUITY
15/02/2026
Q DESTINATION NODE — RECIPIENT
Oncology Precision Med
SPV United States
Amount (USD)
$2.5B
Flow Type
EQUITY
Transaction Date
15/02/2026
Primary Source
View Filing ↗
Funder Profile [ M ]
Entity Eli Lilly and Company
AUM 640000
HQ Location United States
Sector Healthcare
Recipient Profile [ Q ]
Entity Oncology Precision Med
Entity Type SPV
Jurisdiction United States
Intelligence Note

Eli Lilly and Company completed a 2.5 billion dollar equity investment in the Oncology Precision Med hub to advance the development of targeted antibody-drug conjugates for cancer care. This transaction provides the capital for large-scale clinical trials and genomic research facilities. The deal highlights the high institutional value of personalized medical treatments in healthcare.

Σ
Primary Forensic Source https://investor.lilly.com/news-releases/2026/lilly-oncology-precision-med-expansion/
✓ SOURCE LINKED